HTR2A
ENSG00000102468
Target class
GPCR
Chromosome
13
Approved drugs
49
Clinical candidates (approved and in development)
63
- Approved drugs
- 49
- Clinical candidates (approved and in development)
- 63
- Chemical probe available
- Yes
- Other names
- 5-HT2A
- Target name
- HTR2A
- Gene name
- 5-hydroxytryptamine receptor 2A
- Gene symbol
- HTR2A
- Previous gene symbols
- HTR2
- Protein name
- 5-hydroxytryptamine receptor 2A (5-HT-2) (5-HT-2A) (Serotonin receptor 2A)
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 13
- Highest tissue expression
- 15.53
- Tissue specificity (Gini)
- 0.746
- Tissue specificity (tau)
- 0.939
- KEGG gene identifiers
- hsa:3356
- Protein interaction confidence
- 0.861103
- Protein interaction partners
- 29
- R-HSA-390666
- R-HSA-416476
- End position
- 46897076
- Start position
- 46831546
- Chromosome
- 13
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Cell projection, dendrite . Cell projection, axon . Cytoplasmic vesicle . Membrane, caveola . Presynapse .
- PubMed 28129538
- PubMed 36171289
- Tissue specificity (tau)
- 0.93946
- Expression inequality (Gini)
- 0.745705
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 15.53
- Brain - Cortex
- 8.89
- Artery - Tibial
- 7.87
- Brain - Anterior cingulate cortex (BA24)
- 6.03
- Artery - Coronary
- 2.59
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)15.53
- Brain - Cortex8.89
- Artery - Tibial7.87
- Brain - Anterior cingulate cortex (BA24)6.03
- Artery - Coronary2.59
- Brain - Hypothalamus2.54
- Artery - Aorta2.44
- Brain - Amygdala1.67
- Brain - Nucleus accumbens (basal ganglia)1.62
- Testis1.47
- Brain - Hippocampus1.24
- Brain - Caudate (basal ganglia)1.18
- Vagina1.11
- Brain - Substantia nigra0.91
- Fallopian Tube0.79
- Uterus0.74
- Cervix - Ectocervix0.68
- Esophagus - Gastroesophageal Junction0.66
- Colon - Sigmoid0.59
- Brain - Spinal cord (cervical c-1)0.58
- Cervix - Endocervix0.58
- Adipose - Visceral (Omentum)0.5
- Esophagus - Muscularis0.38
- Adipose - Subcutaneous0.35
- Breast - Mammary Tissue0.33
And 29 more, listed on the interactive page.
- GO:0006874
- GO:0007208
- GO:0007210
- GO:0007268
- GO:0009410
- GO:0010513
- GO:0051209
- GO:0070374
- GO:0098664
- GO:0005886
- GO:0098666
- GO:0001587
- GO:0004993
- GO:0005515
- GO:0042802
- GO:0051378
- GO:0071886
increased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pupil diameter
- nervous system
- cardiovascular
- blood
PubMed 28216264platelet aggregation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: platelet aggregation
- nervous system
- cardiovascular
- blood
PubMed 28216264hyperreflexia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hyperreflexia
- nervous system
- cardiovascular
- blood
PubMed 28216264sweating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sweating
- nervous system
- cardiovascular
- blood
PubMed 28216264increased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased body temperature
- nervous system
- cardiovascular
- blood
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
- nervous system
- cardiovascular
- blood
PubMed 28216264stereotypy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: stereotypy
- nervous system
- cardiovascular
- blood
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- cardiovascular
- blood
PubMed 28216264decreased body temperature
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- cardiovascular
- blood
PubMed 28216264psychosis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: psychosis
- nervous system
- cardiovascular
- blood
PubMed 28216264agitation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: agitation
- nervous system
- cardiovascular
- blood
PubMed 28216264myoclonus
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: myoclonus
- nervous system
- cardiovascular
- blood
PubMed 28216264increased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased sleep
- nervous system
- cardiovascular
- blood
PubMed 28216264decreased platelet aggregation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased platelet aggregation
- nervous system
- cardiovascular
- blood
PubMed 28216264increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- nervous system
- cardiovascular
- blood
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- cardiovascular
- blood
PubMed 28216264increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- nervous system
- cardiovascular
- blood
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- nervous system
- cardiovascular
- blood
PubMed 28216264hypervigilance
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hypervigilance
- nervous system
- cardiovascular
- blood
PubMed 28216264hallucinations
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hallucinations
- nervous system
- cardiovascular
- blood
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- cardiovascular
- blood
PubMed 28216264
smooth muscle contraction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: smooth muscle contraction
- cardiovascular system
- central nervous system
PubMed 23197038schizophrenia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: schizophrenia
- cardiovascular system
- central nervous system
PubMed 23197038potential memory impairments
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: potential memory impairments
- cardiovascular system
- central nervous system
PubMed 23197038serotonin syndrome
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: serotonin syndrome
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_h5HT2A, is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT2A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- brain, tissue-based cell-free
Evidence sourceplatelet aggregation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: platelet aggregation
- cardiovascular system
- central nervous system
PubMed 23197038hallucinations
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hallucinations
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (2,587)
- "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
- 12- Week Open Label Treatment of Refractory Bipolar Depression
- 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
- 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
- 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
- 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
- 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Drugs (81)
- Amisulpride Serotonin (5-HT) receptor antagonist
- Aripiprazole Serotonin 2a (5-HT2a) receptor antagonist
- Aripiprazole lauroxil Serotonin 2a (5-HT2a) receptor antagonist
- Asenapine Serotonin 2a (5-HT2a) receptor antagonist
- Asenapine maleate Serotonin 2a (5-HT2a) receptor antagonist
- Blonanserin Serotonin 2a (5-HT2a) receptor antagonist
- Brexpiprazole Serotonin 2a (5-HT2a) receptor antagonist
- Carphenazine Serotonin 2a (5-HT2a) receptor antagonist
- Carphenazine maleate Serotonin 2a (5-HT2a) receptor antagonist
- Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist
- Chlorpromazine hydrochloride Serotonin 2a (5-HT2a) receptor antagonist
- Chlorprothixene Serotonin 2a (5-HT2a) receptor antagonist
- Clothiapine Serotonin 2 (5-HT2) receptor antagonist
- Clozapine Serotonin 2a (5-HT2a) receptor antagonist
- Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist
- Cyclobenzaprine hydrochloride Serotonin 2a (5-HT2a) receptor antagonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Droperidol Serotonin 2a (5-HT2a) receptor antagonist
- Eplivanserin Serotonin 2a (5-HT2a) receptor antagonist